NewcelX Ltd. NCEL
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS2.16
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $1.1M | $992.0K | $1.6M | $9.0M | $5.9M | $99.6K | $897.8K | $708.5K | — |
| SG&A | $1.3M | $805.0K | $1.3M | $6.5M | $5.9M | $2.2M | $3.3M | $2.7M | — |
| Total operating expenses | — | $4.4M | $11.8M | $15.5M | $11.9M | $2.3M | $4.2M | $3.4M | — |
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M | -$11.9M | -$2.3M | -$4.2M | -$3.4M | — |
| Interest expense | — | $45.1K | $119.9K | $95.2K | $48.1K | — | — | — | — |
| Pre-tax income | — | -$7.2M | -$3.3M | — | — | — | — | — | — |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M | -$11.9M | -$2.9M | -$5.4M | -$5.1M | — |
| EPS, basic | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 | -0.41 | — | — | — |
| EPS, diluted | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 | -0.41 | — | — | — |
| Shares, diluted (wtd. avg.) | 3.8M | 3.0M | 3.0M | 492,066 | 11.9M | 7.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.2M | $650.0K | $1.1M | $2.0M | $5.4M | $93.7K | $220.3K | $6.7K | $2.2M |
| Total current assets | $3.2M | $780.0K | $1.8M | $9.2M | $5.7M | $196.7K | $381.7K | — | — |
| Property, plant and equipment | $95.0K | $123.0K | $6.7K | $18.1K | $29.5K | — | — | — | — |
| Goodwill | $1.7M | — | — | — | — | — | — | — | — |
| Total assets | $11.4M | $903.0K | $1.8M | $9.3M | $5.8M | $1.2M | $696.4K | — | — |
| Accounts payable | $251.0K | $605.0K | $4.6M | $2.4M | $1.7M | $4.0M | $2.5M | — | — |
| Short-term debt | $355.0K | $7.7M | — | — | — | — | — | — | — |
| Total current liabilities | $4.2M | $8.9M | $7.9M | $3.4M | $2.4M | $7.2M | $4.0M | — | — |
| Long-term debt | — | — | — | — | — | $113.1K | — | — | — |
| Total liabilities | $4.2M | $8.9M | $10.7M | $6.0M | $5.2M | $10.2M | $6.9M | — | — |
| Retained earnings | -$84.9M | -$76.6M | -$70.4M | -$58.2M | -$41.7M | -$29.8M | -$26.9M | — | — |
| Total equity | $7.2M | -$8.0M | -$1.2M | $111.0K | $542.4K | -$9.0M | -$6.2M | -$8.8M | -$7.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M | -$14.9M | -$729.4K | -$190.0K | -$2.7M | — |
| Depreciation and amortisation | $55.0K | $108.0K | $11.4K | $11.4K | $10.1K | — | — | — | — |
| Stock-based compensation | $765.0K | $208.0K | $149.0K | $22.7K | — | — | — | — | — |
| Capital expenditure | $8.0K | $6.0K | $6.0K | — | $39.6K | — | — | — | — |
| Investing cash flow | $1.7M | -$6.0K | $103.0K | — | -$39.6K | — | — | — | — |
| Financing cash flow | $2.6M | $450.0K | $2.8M | $17.4M | $20.3M | $503.5K | $407.5K | $557.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-049307.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
- Stock-based compensation
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$5.1M | -$5.4M | -$2.9M | -$11.9M | -$16.5M | -$3.3M | -$7.2M | -$8.3M |
| Stock-based compensation | — | — | — | — | — | $22.7K | $149.0K | $208.0K | $765.0K |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |